High court ruling speeds up generic biotech drug approval

The Supreme Court is speeding up the time for generic biotech drugs to become available to the public. The court's unanimous ruling Monday means a loss of billions in sales to makers of original versions.

The justices ruled in favor of generic drug maker Sandoz in its dispute with rival Amgen over a near-copy of Amgen's cancer Neupogen.

The case involves biologics—drugs made from living cells instead of chemicals. The drugs have led to major advances in treating diseases, but come at steep prices.

A 2010 law allows cheaper generic versions known as biosimilars to be produced after a 12-year exclusive run for the original.

The court said companies making biosimilars don't have to wait an extra six months after gaining before selling the drugs.

© 2017 The Associated Press. All rights reserved.

Citation: High court ruling speeds up generic biotech drug approval (2017, June 12) retrieved 26 May 2024 from https://medicalxpress.com/news/2017-06-high-court-biotech-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Justices hear dispute over lower-cost biotech drugs sales


Feedback to editors